Title | GC Pharma Reports Q1 2021 Results | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date of registration | 2021-04-28 | ||||||||||||
Attachment File |
| ||||||||||||
Contents | YONGIN, South Korea, 28 April 2021 - GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2021. First-Quarter Reported Results(1)
(1) Results from continuing operations (Green Cross MS’ blood bag business has been classified as discontinued operations) (2) Results and percentages compare to equivalent 2020 period
●Unconsolidated revenues temporal setback due to termination of in-licence product distribution and vaccine’s international shipping schedule changes ● Maintain double-digit growth in consolidated subsidiaries, including Green Cross MS, Green Cross LabCell and Green Cross Wellbeing ● S/H Flu Vx sales to be reflected in the second quarter unlike prior year, Vx sales expected to be stronger in second half of the year ● Int. sales of Hunterase sales up 412%, as its initial performance in Japan and China was reflected ● In spite of gross margin profit growth 4%p driven by COGs improvement, operating profit impacted by SG&A+R&D cost maintain prior year level
### |